# Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer

> **NCT07718854** · PHASE2 · RECRUITING · sponsor: **Tufts Medical Center** · enrollment: 50 (estimated)

## Conditions studied

- Ovarian Clear Cell Carcinoma
- Metastatic Ovarian Cancer
- Recurrent Ovarian Clear Cell Adenocarcinoma

## Interventions

- **DRUG:** Sacituzumab tirumotecan
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07718854
- **Lead sponsor:** Tufts Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2036-09
- **Final completion:** 2036-09
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07718854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07718854, "Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07718854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*